drug discovery
30 articles about drug discovery in AI news
Anthropic Launches In-House Drug Discovery for Neglected Diseases
Anthropic launched drug discovery for neglected diseases. Novartis CEO says AI could cut development from 12 to 7-8 years and double success rates.
DrugPlayGround Benchmark Tests LLMs on Drug Discovery Tasks
A new framework called DrugPlayGround provides the first standardized benchmark for evaluating large language models on key drug discovery tasks, including predicting drug-protein interactions and chemical properties. This addresses a critical gap in objectively assessing LLMs' potential to accelerate pharmaceutical research.
Beyond General AI: How Liquid Foundation Models Are Revolutionizing Drug Discovery
Researchers have developed MMAI Gym, a specialized training platform that teaches AI the 'language of molecules' to create more efficient drug discovery models. The resulting Liquid Foundation Models outperform larger general-purpose AI while requiring fewer computational resources.
Eli Lilly Signs $2.75B AI Drug Discovery Deal with Insilico Medicine
Eli Lilly has entered a $2.75 billion licensing pact with Insilico Medicine for multiple AI-discovered drug programs. The deal includes an upfront payment, milestones, and royalties, marking a major validation for AI-driven pharmaceutical R&D.
OpenAI Launches GPT-Rosalind for Drug Discovery, GPT-5.4-Cyber for Security
OpenAI launched GPT-Rosalind, a life sciences model performing above the 95th percentile of human experts on novel biological data, and GPT-5.4-Cyber, a cybersecurity variant. These releases, alongside a major Agents SDK update, signal a pivot from general AI to specialized, high-stakes enterprise domains.
RxnNano: How a Tiny AI Model Outperforms Giants in Chemical Discovery
Researchers have developed RxnNano, a compact 0.5B-parameter AI model that outperforms models ten times larger in predicting chemical reactions. Using innovative training techniques that prioritize chemical understanding over brute-force scaling, it achieves 23.5% better accuracy on key benchmarks for drug discovery applications.
XtalPi's Profit Milestone Signals AI's Transformative Impact on Pharmaceutical Discovery
Chinese AI drug discovery firm XtalPi projects its first annual profit in 2025 following a 193% revenue surge, marking a pivotal moment for AI-driven pharmaceutical research. The company's turnaround demonstrates the commercial viability of AI in accelerating drug development pipelines.
Lilly's AI Factory: How a 9,000+ GPU SuperPOD is Rewriting Pharmaceutical Discovery
Eli Lilly has launched 'LillyPod,' the world's most powerful privately-owned AI factory for drug discovery. Powered by NVIDIA's new DGX B300 systems with over 1,000 Blackwell Ultra GPUs, it promises to accelerate medical breakthroughs at unprecedented scale.
BMS Builds Life Science’s Largest AI Cluster on 8 Vera Rubin NVL72 Systems
BMS deploys second NVIDIA DGX SuperPOD on 8 Vera Rubin NVL72 systems, delivering 10x perf/W for AI drug discovery.
AI Firms Target Biotech for High-Impact, High-Margin Applications
A trend analysis notes AI companies are shifting focus to biotech, where accurate prediction models can be monetized through drug discovery and synthetic biology, creating a new competitive frontier.
OpenAI's 'Autonomous AI Researchers' Vision Sparks Debate on Biology's 'ChatGPT Moment'
A tweet highlights OpenAI's repeated references to 'autonomous AI researchers' as signaling a 'ChatGPT moment for biology,' suggesting AI could accelerate drug discovery by orders of magnitude. The claim draws a direct analogy to AlphaFold's impact on structural biology.
The AI-Powered 'Cocktail': How One Injection Could Revolutionize Healthcare by 2029
A leading AI researcher predicts that within five years, personalized medical treatments delivered via single injections or pills will become reality. This breakthrough promises to democratize access to advanced healthcare through AI-driven drug discovery and delivery systems.
From Code to Discovery: The Next Frontier of AI Agents in Research
AI researcher Omar Saray predicts a shift from 'agentic coding' to 'agentic research'—where AI systems will autonomously conduct scientific discovery. This evolution promises to accelerate innovation across disciplines.
Anthropic's Fable 5 Beta Shows 10x Drug Design Speedup Ahead of IPO
Anthropic's Fable 5 beta achieved 10x speedup in protein design before being pulled from testing, signaling enterprise monetization ahead of IPO.
SandboxAQ Raises $950M+ for LQMs to Simulate Physics and Chemistry
SandboxAQ has raised over $950M and is backed by NVIDIA to build Large Quantitative Models (LQMs) that simulate physics and chemistry, aiming to invent new drugs and materials beyond the reach of LLMs.
Researchers Achieve Ultra-Long-Horizon Agentic Science with Cohesive AI Agents
A research team has developed AI agents capable of executing and maintaining coherent, long-horizon scientific research workflows. This addresses a core challenge in creating autonomous systems for complex discovery.
Anthropic Acquires AI Biotech Coefficient Bio for ~$400M to Build 'Virtual Biologist'
Anthropic acquired AI biotech startup Coefficient Bio for approximately $400M. The small team was building AI to plan drug R&D, manage clinical strategy, and identify new drug opportunities, aligning with CEO Dario Amodei's vision of AI as a 'virtual biologist.'
BloClaw: New AI4S 'Operating System' Cuts Agent Tool-Calling Errors to 0.2% with XML-Regex Protocol
Researchers introduced BloClaw, a unified operating system for AI-driven scientific discovery that replaces fragile JSON tool-calling with a dual-track XML-Regex protocol, cutting error rates from 17.6% to 0.2%. The system autonomously captures dynamic visualizations and provides a morphing UI, benchmarked across cheminformatics, protein folding, and molecular docking.
Anthropic Launches Claude Science as New Flagship
Anthropic launched Claude Science as a new flagship for computational biology and Claude Sonnet 5 with a stealth 30% effective price increase via a new tokenizer.
BioMatrix: A single decoder reads proteins, molecules, language on 304B tokens
BioMatrix, a decoder-only biological foundation model, achieves SOTA on 77 of 80 tasks after training on 304B tokens of sequences, structures, and language.
NVIDIA Vera Rubin: One Rack Matches TOP500, 35 EU Labs Deploy
NVIDIA's Vera Rubin NVL72 delivers TOP500-class performance in a single rack, with 35 European labs deploying the system for AI and HPC.
Google DeepMind loses its third senior AI researcher in months as Nobel laureate John Jumper joins Anthropic
Nobel laureate John Jumper, DeepMind Director and VP Engineering Fellow who co-created AlphaFold, has left Google after nine years for Anthropic. The move follows Noam Shazeer's exit to OpenAI two days earlier — less than two years after Google paid $2.7B to reacquire him — and David Silver's Januar
Anthropic: AI agents fail biology retrieval, miss 261 Ebola sequences
Anthropic research shows Claude Sonnet 4 returning 5–106 Ebola sequences instead of 266, shifting outbreak origin from 2014 to 1922. Repeatable retrieval tool fixes the variance.
MIT Paper Formalizes Self-Revising AI Scientists That Can Change Their Own Language
MIT paper 2606.01444 formalizes self-revising AI scientists that can change their conceptual schema. Novelty is defined by what could not be expressed in the previous framework.
MorphoHELM Benchmark Finds Classic CV Beats Deep Learning on Cell Painting
MorphoHELM benchmark from Microsoft evaluates 20+ methods for Cell Painting, finding no deep learning model beats classic CV when batch effects are controlled.
Hims & Hers to Launch AI Weight-Loss Agent as GLP-1 Demand Surges
Hims & Hers to launch AI weight-loss agent for GLP-1 users, announced during Q1 2026 earnings call. Revenue grew 25% to $420M.
Claude Solves Bioinformatics Problems Human Experts Miss
Anthropic shows Claude solves 23 bioinformatics problems human experts missed, catching errors in genomic analyses.
GPT-5.5 Launches: The Super App Strategy, Not the Model
OpenAI released GPT-5.5, codenamed Spud, 48 days after GPT-5.4. The model itself is less interesting than the super app strategy, 35x cost reduction on GB200 hardware, and 48-day release cadence that signals a deliberate acceleration.
AI-Driven Age-Reversal Therapy Enters First Human Trials
An AI-discovered therapeutic approach for biological age reversal has advanced to its first human trials. This milestone validates the use of AI for identifying novel geroprotective compounds.
Anthropic Appoints Novartis CEO Vas Narasimhan to Board via Benefit Trust
Anthropic's independent governance body appointed Vas Narasimhan, CEO of pharmaceutical giant Novartis, to its board. This move connects frontier AI development directly with global healthcare leadership.